New cough drug shows promise in early trial

NCT ID NCT04866563

Completed Symptom relief Sponsor: Axalbion SA Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 study tested a new drug called AX-8 in 108 adults with chronic cough that either has no known cause or doesn't get better with treatment. The goal was to see if AX-8 could reduce how often people cough. Participants took either AX-8 or a placebo, and coughs were counted using a recording device. The study is now complete, and results will help decide if larger trials are needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AX-8 (orally disintegrating tablet)
What this could lead to: If successful, AX-8 could offer a new treatment option to reduce coughing in people with chronic cough that has no clear cause or hasn't responded to other treatments.
What could go wrong: This is an early Phase 2 trial with only 108 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC COUGH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC COUGH

Contacts and locations

Show contact details

Locations

Axalbion Study Site 4401

London, England, SE5 9RS, United Kingdom
Axalbion Study Site 4402

London, England, SW3 6HP, United Kingdom
Axalbion Study Site 4403

Manchester, England, M23 9LT, United Kingdom
Axalbion Study Site 4404

Broughton, England, DN20 0HR, United Kingdom
Axalbion Study Site 4405

North Shields, England, NE29 8NH, United Kingdom
Axalbion Study Site 4406

Birmingham, England, B9 5SS, United Kingdom
Axalbion Study Site 4407

Oxford, England, OX3 9DU, United Kingdom
Axalbion Study Site 4408

Newport, Wales, NP20 2EF, United Kingdom
Axalbion Study Site 4409

Chelmsford, England, CM1 7ET, United Kingdom
Axalbion Study Site 4410

London, England, W2 1NY, United Kingdom
Axalbion Study Site 4411

Preston, England, PR2 9HT, United Kingdom
Axalbion Study Site 4412

Shipley, England, BD18 3SA, United Kingdom
Axalbion Study Site 4413

Coventry, England, CV3 4FJ, United Kingdom
Axalbion Study Site 4414

Belfast, BT9 7AB, United Kingdom
Axalbion Study Site 4415

Northwood, HA6 2RN, United Kingdom
Axalbion Study Site 4417

Orpington, England, BR5 3QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.